Brazil’s Butantan-DV single-dose dengue vaccine was authorised on 26 November for people aged 12–59. Trials with 16,000 volunteers showed high efficacy, and the vaccine will join the national programme in early 2026.
Photo by KOBU Agency, Unsplash
Emory University measured antibody responses in 24 people after the 2023–24 monovalent vaccine targeting Omicron XBB.1.5. The study found long-lasting antibodies, cross-reactive protection with the ancestral WA1 strain, and a 2.8-fold boost from immune imprinting.
A new study suggests that giving access to RSV vaccines all year can help reduce the risk of outbreaks. This is especially important for infants in both cities and rural areas.
No more articles